ONLINE DATABASE SEARCH - HIV-LS-296-MEMO
1. 43381 HIV-LS-296; PUBMED-HIV-5/18/2004
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
Yamamoto, N, Yang, R, Yoshinaka, Y, Amari, S, Nakano, T, Cinatl, J, Rabenau, H, Doerr, HW, Hunsmann, G, Otaka, A, Tamamura, H, Fujii, N, and Yamamoto, N
Biochem Biophys Res Commun 2004. 318(3): 719-25
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15144898&dopt=abstract
2. 43382 HIV-LS-296; PUBMED-HIV-5/18/2004
Human Immunodeficiency Virus Type 1 (HIV-1) Integrase: Resistance to Diketo Acid Integrase Inhibitors Impairs HIV-1 Replication and Integration and Confers Cross-Resistance to L-Chicoric Acid
Lee, DJ and Robinson, WE Jr
J Virol 2004. 78(11): 5835-47
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15140981&dopt=abstract
3. 43383 HIV-LS-296; PUBMED-HIV-5/18/2004
Structure-Based Design and Synthesis of Non-Nucleoside, Potent, and Orally Bioavailable Adenosine Deaminase Inhibitors
Terasaka, T, Okumura, H, Tsuji, K, Kato, T, Nakanishi, I, Kinoshita, T, Kato, Y, Kuno, M, Seki, N, Naoe, Y, Inoue, T, Tanaka, K, and Nakamura, K
J Med Chem 2004. 47(11): 2728-2731
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15139750&dopt=abstract
4. 43384 HIV-LS-296; PUBMED-HIV-5/18/2004
High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma
Rezk, NL, Tidwell, RR, and Kashuba, AD
J Chromatogr B Analyt Technol Biomed Life Sci 2004. 805(2): 241-7
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15135096&dopt=abstract
5. 43385 HIV-LS-296; PUBMED-HIV-5/18/2004
Antiviral profile of HIV inhibitors in macrophages: implications for therapy
Perno, CF, Balestra, E, Francesconi, M, Abdelahad, D, Calio, R, Balzarini, J, and Aquaro, S
Curr Top Med Chem 2004. 4(9): 1009-15
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15134554&dopt=abstract
6. 43386 HIV-LS-296; EMBASE-HIV-5/18/2004
Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy
Yehia, Nasser AM, Antuch, Walfrido, Beck, Barbara, Hess, Sibylle, Schauer-Vukasinovic, Vesna, Almstetter, Michael, Furer, Patrick, Herdtweck, Eberhardt, and Domling, Alexander
Bioorganic & Medicinal Chemistry Letters 2004. In Press, Corrected Proof
HYPERLINK: http://www.sciencedirect.com/science/article/B6TF9-4CB07PR-C/2/e414ecf323b0234aa60aa43abe86c3a5
7. 43387 HIV-LS-296; EMBASE-HIV-5/18/2004
The viral infectivity factor (Vif) of HIV-1 unveiled
Rose, Kristine M, Marin, Mariana, Kozak, Susan L, and Kabat, David
Trends in Molecular Medicine 2004. In Press, Corrected Proof
HYPERLINK: http://www.sciencedirect.com/science/article/B6W7J-4CC7P82-3/2/bab6ab2256ef89d34c8b13eb87b110f5
8. 43388 HIV-LS-296; EMBASE-HIV-5/18/2004
Isolation and characterization of anti-HIV peptides from Dorstenia contrajerva and Treculia obovoidea
Bokesch, Heidi R, Charan, Romila D, Meragelman, Karina M, Beutler, John A, Gardella, Roberta, O'Keefe, Barry R, McKee, Tawnya C, and McMahon, James B
FEBS Letters 2004. In Press, Uncorrected Proof
HYPERLINK: http://www.sciencedirect.com/science/article/B6T36-4CCCT3R-2/2/023860a033aed26c64893351f6b27672
9. 43389 HIV-LS-296; PUBMED-HIV-5/18/2004
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase
Sharma, PL, Nurpeisov, V, Hernandez-Santiago, B, Beltran, T, and Schinazi, RF
Curr Top Med Chem 2004. 4(9): 895-919
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15134548&dopt=abstract
10. 43390 HIV-LS-296; EMBASE-HIV-5/18/2004
Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets
Ohtaka, Hiroyasu, Muzammil, Salman, Schon, Arne, Velazquez-Campoy, Adrian, Vega, Sonia, and Freire, Ernesto
The International Journal of Biochemistry & Cell Biology 2004. In Press, Corrected Proof
HYPERLINK: http://www.sciencedirect.com/science/article/B6TCH-4CBVKTD-2/2/9d242653dee9627e420ce4274cc03c7f
11. 43391 HIV-LS-296; EMBASE-HIV-5/18/2004
Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs
Sarafianos, Stefan G, Hughes, Stephen H, and Arnold, Eddy
The International Journal of Biochemistry & Cell Biology 2004. In Press, Corrected Proof
HYPERLINK: http://www.sciencedirect.com/science/article/B6TCH-4CBVS67-4/2/dbc0a5428d09b1b68415773ac2c85e98
12. 43392 HIV-LS-296; PUBMED-HIV-5/18/2004
Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activity of 1-Benzothiepine 1,1-Dioxide and 1-Benzazepine Derivatives Containing a Tertiary Amine Moiety
Seto, M, Aramaki, Y, Okawa, T, Miyamoto, N, Aikawa, K, Kanzaki, N, Niwa, S, Iizawa, Y, Baba, M, and Shiraishi, M
Chem Pharm Bull (Tokyo) 2004. 52(5): 577-90
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15133211&dopt=abstract
13. 43393 HIV-LS-296; PUBMED-HIV-5/18/2004
A hierarchical model of HIV-1 protease drug resistance
Goodsell, DS
Appl Bioinformatics 2002. 1(1): 3-12
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15130852&dopt=abstract
14. 43394 HIV-LS-296; PUBMED-HIV-5/18/2004
In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease
Sumpter, LR, Inayat, MS, Yost, EE, Duvall, W, Hagan, E, Mayhew, CN, Elford, HL, and Gallicchio, VS
Antiviral Res 2004. 62(3): 111-20
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15130534&dopt=abstract
15. 43395 HIV-LS-296; PUBMED-HIV-5/18/2004
Antiretrovirals, part 1: overview, history, and focus on protease inhibitors
Wynn, GH, Zapor, MJ, Smith, BH, Wortmann, G, Oesterheld, JR, Armstrong, SC, and Cozza, KL
Psychosomatics 2004. 45(3): 262-70
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15123854&dopt=abstract
16. 43396 HIV-LS-296; PUBMED-HIV-5/18/2004
Are fusion inhibitors active against all HIV variants?
Poveda, E, Rodes, B, Toro, C, and Soriano, V
AIDS Res Hum Retroviruses 2004. 20(3): 347-8
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15117459&dopt=abstract
17. 43397 HIV-LS-296; PUBMED-HIV-5/18/2004
Mutations in HIV-1 Reverse Transcriptase Potentially Associated with Hypersusceptibility to Nonnucleoside Reverse-Transcriptase Inhibitors: Effect on Response to Efavirenz-Based Therapy in an Urban Observational Cohort
Tozzi, V, Zaccarelli, M, Narciso, P, Trotta, MP, Ceccherini-Silberstein, F, De, Longis P, D'Offizi, G, Forbici, F, D'Arrigo, R, Boumis, E, Bellagamba, R, Bonfigli, S, Carvelli, C, Antinori, A, and Perno, CF
J Infect Dis 2004. 189(9): 1688-95
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15116307&dopt=abstract
18. 43398 HIV-LS-296; PUBMED-HIV-5/18/2004
Blocking of Human Immunodeficiency Virus Type-1 Virion Autolysis by Autologous p2(gag) Peptide
Misumi, S, Morikawa, Y, Tomonaga, M, Ohkuma, K, Takamune, N, and Shoji, S
J Biochem (Tokyo) 2004. 135(3): 447-53
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15113844&dopt=abstract
19. 43399 HIV-LS-296; PUBMED-HIV-5/18/2004
Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs
Zhang, XW and Yap, YL
Bioorg Med Chem 2004. 12(10): 2517-21
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15110833&dopt=abstract
20. 43400 HIV-LS-296; EMBASE-HIV-5/18/2004
Green tea polyphenol epigallocatechin gallate binding to CD4 as a model for the inhibition of HIV-1-gp120 binding to CD4+ T cells
McCormick, TG, Nance, CL, Williamson, MP, and Shearer, WT
Journal of Allergy and Clinical Immunology 2004. 113(2, Supplement 1): S256
HYPERLINK: http://www.sciencedirect.com/science/article/B6WH4-4BRJ5RW-151/2/314fd3049fa9bc8479c3797d32528777
21. 43401 HIV-LS-296; PUBMED-HIV-5/18/2004
Threshold interaction energy of NRTI's (2(')-deoxy 3(')-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition
Yadav, A and Singh, SK
Bioorg Med Chem Lett 2004. 14(10): 2677-80
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15109677&dopt=abstract
22. 43402 HIV-LS-296; PUBMED-HIV-5/18/2004
Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity
Benard, C, Zouhiri, F, Normand-Bayle, M, Danet, M, Desmaele, D, Leh, H, Mouscadet, JF, Mbemba, G, Thomas, CM, Bonnenfant, S, Le, Bret M, and D'Angelo, J
Bioorg Med Chem Lett 2004. 14(10): 2473-6
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15109635&dopt=abstract
23. 43403 HIV-LS-296; PUBMED-HIV-5/18/2004
Heterogeneity of Envelope Molecules Shown by Different Sensitivities to Anti-V3 Neutralizing Antibody and CXCR4 Antagonist Regulates the Formation of Multiple-Site Binding of HIV-1
Harada, S, Yusa, K, and Maeda, Y
Microbiol Immunol 2004. 48(4): 357-65
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15107547&dopt=abstract
24. 43404 HIV-LS-296; PUBMED-HIV-5/18/2004
Adsorption and infectivity of human immunodeficiency virus type 1 are modified by the fluidity of the plasma membrane for multiple-site binding
Harada, S, Akaike, T, Yusa, K, and Maeda, Y
Microbiol Immunol 2004. 48(4): 347-55
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15107546&dopt=abstract
25. 43405 HIV-LS-296; PUBMED-HIV-5/18/2004
Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection
Kensinger, RD, Catalone, BJ, Krebs, FC, Wigdahl, B, and Schengrund, CL
Antimicrob Agents Chemother 2004. 48(5): 1614-23
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15105112&dopt=abstract
26. 43406 HIV-LS-296; PUBMED-HIV-5/18/2004
A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease
Vega, S, Kang, LW, Velazquez-Campoy, A, Kiso, Y, Amzel, LM, and Freire, E
Proteins 2004. 55(3): 594-602
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15103623&dopt=abstract
27. 43407 HIV-LS-296; PUBMED-HIV-5/18/2004
Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected With Non-B HIV-1 Variants and Matched Patients Infected With HIV-1 Subtype B
Montes, B, Vergne, L, Peeters, M, Reynes, J, Delaporte, E, and Segondy, M
J Acquir Immune Defic Syndr 2004. 35(4): 329-336
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15097148&dopt=abstract
28. 43408 HIV-LS-296; PUBMED-HIV-5/18/2004
Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro
Wang, JH, Tam, SC, Huang, H, Ouyang, DY, Wang, YY, and Zheng, YT
Biochem Biophys Res Commun 2004. 317(4): 965-71
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15094363&dopt=abstract
29. 43409 HIV-LS-296; WOS-HIV-5/09/2004
Interaction of HIV-1 reverse transcriptase with modified oligonucleotide primers containing 2 '-O-beta-D-ribofuranosyladenosine
Golubeva, AS, Ermolinsky, BS, Efimtseva, EV, Tunitskaya, VL, van, Aerschot A, Herdewijn, P, Mikhailov, SN, and Kochetkov, SN
BIOCHEMISTRY-MOSCOW+ 2004. 69(2): 130-136
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220754400002
30. 43410 HIV-LS-296; WOS-HIV-5/16/2004
Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis
Julias, JG, Boyer, PL, McWilliams, MJ, Alvord, WG, and Hughes, SH
VIROLOGY 2004. 322(1): 13-21
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220861100002
31. 43411 HIV-LS-296; WOS-HIV-5/16/2004
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion
Xu, HZ, Svarovskaia, ES, Barr, R, Zhang, YJ, Khan, MA, Strebel, K, and Pathak, VK
P NATL ACAD SCI USA 2004. 101(15): 5652-5657
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220861500064
32. 43412 HIV-LS-296; WOS-HIV-5/16/2004
Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4(+) T lymphocytes
Maranon, C, Desoutter, JF, Hoeffel, G, Cohen, W, Hanau, D, and Hosmalin, A
P NATL ACAD SCI USA 2004. 101(16): 6092-6097
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220978000075
33. 43413 HIV-LS-296; WOS-HIV-5/16/2004
Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities
Ishikawa, T, Nishigaya, K, Takami, K, Uchikoshi, H, Chen, IS, and Tsai, IL
J NAT PROD 2004. 67(4): 659-663
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000221001000021
34. 43414 HIV-LS-296; WOS-HIV-5/16/2004
Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues
Udier-Blagovic, M, Tirado-Rives, J, and Jorgensen, WL
J MED CHEM 2004. 47(9): 2389-2392
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220918500023
35. 43415 HIV-LS-296; WOS-HIV-5/16/2004
Once-daily protease inhibitor - REYATAZ (TM) (atazanavir) - Approved by European Commission for treatment-experienced people with HIV
Simond, A
INFECTION 2004. 32(2): A8
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000221002900014
36. 43416 HIV-LS-296; WOS-HIV-5/16/2004
Polyamidoamine dendrimers inhibit binding of Tat peptide to TAR RNA
Zhao, H, Li, JR, Xi, F, and Jiang, L
FEBS LETT 2004. 563(1-3): 241-245
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220773200045
37. 43417 HIV-LS-296; WOS-HIV-5/16/2004
Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it
Hamer, DH
CURR HIV RES 2004. 2(2): 99-111
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220935000001
38. 43418 HIV-LS-296; WOS-HIV-5/16/2004
Progress towards the development of a HIV-1 gp41-directed vaccine
McGaughey, GB, Barbato, G, Bianchi, E, Freidinger, RM, Garsky, VM, Hurni, WM, Joyce, JG, Liang, XP, Miller, MD, Pessi, A, Shiver, JW, and Bogusky, MJ
CURR HIV RES 2004. 2(2): 193-204
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220935000009
39. 43419 HIV-LS-296; WOS-HIV-5/16/2004
Pharmacokinetic enhancement of protease inhibitor therapy
King, JR, Wynn, H, Brundage, R, and Acosta, EP
CLIN PHARMACOKINET 2004. 43(5): 291-310
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220989400003
40. 43420 HIV-LS-296; WOS-HIV-5/16/2004
Enhancement of the inhibitory activity of oatp, antisense oligonucleotides by incorporation of 2 '-O,4 '-C-ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity
Takagi, M, Morita, K, Nakai, D, Nakagomi, R, Tokui, T, and Koizumi, M
BIOCHEMISTRY-US 2004. 43(15): 4501-4510
HYPERLINK:
http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220812900011